• Date of Publication: 28 April 2022
• Status:  With Final HTA Council Recommendation
• Type of Health Technology: Drugs
• HTA Track: Expedited Track
• Topic Assignment: Internal Assessment Group
• Recommendation Status:  Available
  The HTA Council affirms that the previous recommendation on tocilizumab (10 May 2021) still stands based on the new studies and updated recommendations of the WHO and Philippine COVID-19 Living CPG.
  • The HTA Council recommends the use of tocilizumab in addition to systemic steroids, in patients showing respiratory deterioration and/or requiring high doses of oxygen and with elevated markers of inflammation.
    • The recommended indication by HTAC matched with the approved therapeutic indication for COVID-19 of tocilizumab. “Treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation”
  • The HTA Council recommends against the use of tocilizumab among patients with COVID-19 infection who do not require oxygen supplementation.
    
• Secretary of Health Decision Status: Available
• Evidence and Relevant Links:
  • HTA Council Recommendation

• Evidence Summary
• Secretary of Health Decision

History

• Tocilizumab for treatment of COVID-19 (2021 Assessment)